ftInvstr
HIKAL · Healthcare ₹222.9 -7.4% Mkt Cap ₹2726 Cr overvalued
← Search another stock

HIKAL

Healthcare Drug Manufacturers - Specialty & Generic
★ Watchlist ⧉ Add to bucket
₹222.9
-7.4% today · 30d +3.15%
as of 2026-09-04
Price · Daily Candles
AI narrative is temporarily unavailable for HIKAL. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2025-12-31
REVENUE
₹494 Cr
+10.41% YoY
NET PROFIT
₹-6 Cr
-134.3% YoY
OPM
17.2%
+0.43pp YoY
EPS
₹-0.48
Intrinsic value · DCF ₹96.02 · Margin of safety -56.9% (overvalued) · FCF yield 5.25%
◇ Sector Position
PEERPEROCE %
HIKAL30.0210.0
SUNPHARMA37.5721.44
DIVISLAB89.1821.56
ZYDUSLIFE24.6424.22
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
62
SCORE / 100
Overall
6-axis composite of the sections below.
Performance NEUTRAL 40
Valuation FAIR 40
Growth STEADY 65
Profitability DECENT 68
Technicals NEUTRAL 67
Risk LOW 90
Key Stats
P/B
2.5
52W HIGH
₹282.7
OFF HIGH
-21.15%
DIV YIELD
0.27%
MKT CAP
₹2726 Cr
◉ Active Signals
MACDNeutral1.8273
RSI(14)Neutral54.37
Street Consensus
1 analyst
₹300.0
mean target
Low ₹300.0Now ₹222.9High ₹300.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold HIKAL and at what entry.

Sign up freeSign in
AI-generated research based on publicly available data and ftInvstr's bias-safe quantitative models. Not investment advice. Past performance does not guarantee future results. Consult a SEBI-registered investment adviser before making any investment decision.